Correlation Engine 2.0
Clear Search sequence regions


  • 1A1 (1)
  • allergen (12)
  • asthma (1)
  • CCL23 (1)
  • CCL5 (1)
  • cohort (2)
  • CXCL8 (1)
  • fever (1)
  • humans (1)
  • il 24 protein (1)
  • IL24 (2)
  • il7 (1)
  • patients (2)
  • protein human (1)
  • protein levels (1)
  • rhinitis (1)
  • rna (2)
  • scgb1a1 protein, human (1)
  • secretoglobin (1)
  • sputum (2)
  • Uteroglobin (2)
  • Sizes of these terms reflect their relevance to your search.

    While several systemic immunomodulatory effects of allergen-specific immunotherapy (AIT) have been discovered, local anti-inflammatory mechanisms in the respiratory tract are largely unknown. We sought to elucidate local and epithelial mechanisms underlying allergen-specific immunotherapy in a genome-wide approach. We induced sputum in hay fever patients and healthy controls during the pollen peak season and stratified patients by effective allergen immunotherapy or as untreated. Sputum was directly processed after induction and subjected to whole transcriptome RNA microarray analysis. Nasal secretions were analyzed for Secretoglobin1A1 (SCGB1A1) and IL-24 protein levels in an additional validation cohort at three defined time points during the 3-year course of AIT. Subsequently, RNA was extracted and subjected to an array-based whole transcriptome analysis. Allergen-specific immunotherapy inhibited pro-inflammatory CXCL8, IL24, and CCL26mRNA expression, while SCGB1A1, IL7, CCL5, CCL23, and WNT5BmRNAs were induced independently of the asthma status and allergen season. In our validation cohort, local increase of SCGB1A1 occurred concomitantly with the reduction of local IL-24 in upper airways during the course of AIT. Additionally, SCGB1A1 was identified as a suppressor of epithelial gene expression. Allergen-specific immunotherapy induces a yet unknown local gene expression footprint in the lower airways that on one hand appears to be a result of multiple regulatory pathways and on the other hand reveals SCGB1A1 as novel anti-inflammatory mediator of long-term allergen-specific therapeutic intervention in the local environment. © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

    Citation

    Ulrich M Zissler, Constanze A Jakwerth, Ferdinand Guerth, Larissa Lewitan, Sandra Rothkirch, Miodrag Davidovic, Moritz Ulrich, Madlen Oelsner, Holger Garn, Carsten B Schmidt-Weber, Adam M Chaker. Allergen-specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways. Allergy. 2021 Aug;76(8):2461-2474

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33528894

    View Full Text